PT - JOURNAL ARTICLE AU - Thomson, Tina AU - Prendecki, Maria AU - Gleeson, Sarah AU - Martin, Paul AU - Spensley, Katrina J AU - Cardoso De Aguiar, Rute AU - Sandhu, Bynvant AU - Seneschall, Charlotte AU - Gan, Jaslyn AU - Clarke, Candice L. AU - Lewis, Shanice AU - Pickard, Graham AU - Thomas, David AU - McAdoo, Stephen P. AU - Lightstone, Liz AU - Cox, Alison AU - Kelleher, Peter AU - Willicombe, Michelle TI - Immune responses following 3<sup>rd</sup> and 4<sup>th</sup> doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients AID - 10.1101/2022.04.29.22274396 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.29.22274396 4099 - http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274396.short 4100 - http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274396.full AB - Background Solid organ transplant recipients have attenuated immune responses to SARS-CoV-2 vaccines. In this study, we report on immune responses to 3rd- (V3) and 4th- (V4) doses of heterologous and homologous vaccines in a kidney transplant population.Methods 724 kidney transplant recipients were prospectively screened for serological responses following 3 primary doses of a SARS-CoV2 vaccine. 322 patients were sampled post-V4 for anti-spike (anti-S), with 69 undergoing assessment of SARS-CoV-2 T-cell responses. All vaccine doses were received post-transplant, only mRNA vaccines were used for V3 and V4 dosing. All participants had serological testing performed post-V2 and at least once prior to their 1st dose of vaccine.Results 586/724 (80.9%) patients were infection-naïve post-V3; 141/2586 (24.1%) remained seronegative at 31 (21-51) days post-V3. Timing of vaccination in relation to transplantation, OR: 0.28 (0.15-0.54), p=0.0001; immunosuppression burden, OR: 0.22 (0.13-0.37), p&lt;0.0001, and a diagnosis of diabetes, OR: 0.49 (0.32-0.75), p=0.001, remained independent risk factors for non-seroconversion. Seropositive patients post-V3 had greater anti-S if primed with BNT162b2 compared with ChAdOx1, p=0.001.Post-V4, 45/239 (18.8%) infection-naïve patients remained seronegative. De novo seroconversion post-V4 occurred in 15/60 (25.0%) patients who were seronegative post-V3. There was no difference in anti-S post-V4 by vaccine combination, p=0.50. Anti-S post-V4 were sequentially greater in those seroconverting post V2- compared with V3-, and V3- compared with V4-, at 1561 (567-5211), 379 (101-851) and 19 (9.7-48) BAU/ml respectively.T-cell responses were poor, with only 11/54 (20.4%) infection-naive patients having detectable T-cell responses post-V4, with no difference seen by vaccine type.Conclusion A significant proportion of transplant recipients remain seronegative following 3- and 4- doses of SARS-CoV-2 vaccines, with poor T-cell responses, and are likely to have inadequate protection against infection.Competing Interest StatementMW/PK have received study support for this work from Oxford Immunotec.Funding StatementThe study received support from The Nan Diamond FundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Wales Research Ethics Committee 1 (Reference: 20/WA/0123) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript